An act relating to treatment for opioid use disorder in correctional facilities
H.32 would overhaul how the Vermont Department of Corrections provides treatment for opioid use disorder in correctional facilities. The bill requires the department to enter into memorandums of understanding with the opioid treatment program nearest each correctional facility, and authorizes agreements with nearby office-based opioid treatment providers, so inmates can receive medication for opioid use disorder and related services while incarcerated. It also directs the department to ensure continuity of care from intake through release, including screening, initiation of treatment when medically necessary, continuation of existing prescriptions, counseling and behavioral therapy, and coordination with community providers.
The bill also expands reentry planning for people leaving custody. It requires individualized reentry plans for inmates receiving medication for opioid use disorder, including scheduled follow-up appointments, discharge summaries, a short supply of medication at release when appropriate, and case management to support adherence and recovery. In addition, the bill requires annual reporting to legislative committees on utilization, recidivism, costs, and post-release outcomes, and it mandates staff training on medication for opioid use disorder. A separate report due in 2026 would outline a plan for federal certification of opioid treatment programs at correctional facilities and a transition from outside-provider memorandums of understanding to in-house services. The department is also directed to seek grants to support training, technology, and care-coordination infrastructure.
The bill amends 28 V.S.A. § 801 and creates substantial new requirements in 28 V.S.A. § 801b governing medical care and medication for opioid use disorder in correctional facilities. It would require the Department of Corrections to formalize access to opioid treatment programs and office-based opioid treatment providers, expand access to buprenorphine, methadone, and other clinically appropriate medications, and establish detailed procedures for continuation, initiation, discontinuation, and discharge planning. The bill would affect incarcerated people with opioid use disorder, correctional health contractors, community treatment providers, and DOC staff, while also creating new reporting and training obligations for the department.
The bill appears strongly supportive of expanding evidence-based treatment for opioid use disorder in correctional settings. Its stated legislative intent emphasizes equal access to coordinated, accessible care comparable to Vermont’s community hub-and-spoke system, and the structure of the bill reflects a public-health-oriented approach focused on continuity of care and reentry support. No committee transcripts or recorded votes were provided, so there is no documented opposition or formal vote history in the supplied materials.
The main potential points of contention are operational and clinical rather than ideological. The bill requires DOC to work with outside opioid treatment programs and office-based providers, which may raise questions about staffing, security, logistics, and cost. It also contemplates future federal certification of correctional facility opioid treatment programs, suggesting that the current model may be viewed as an interim step rather than a final solution. Another possible area of debate is the balance between mandatory treatment access and provider clinical judgment, especially around initiation, continuation, and discontinuation of medication, but no specific objections are recorded in the provided context.